PDGFR Inhibitors
Items 21 to 26 of 26 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
VEGFR2 Kinase Inhibitor III | 204005-46-9 | sc-202851 | 5 mg | $162.00 | 7 | |
VEGFR2 Kinase Inhibitor III demonstrates a remarkable capacity to modulate PDGFR activity through selective binding that alters receptor conformation. This compound engages in specific electrostatic interactions, facilitating a unique inhibition mechanism that impacts downstream signaling cascades. Its kinetic profile indicates a rapid onset of action, with a notable half-life that allows for extended receptor modulation. The compound's structural features promote targeted engagement, influencing cellular behavior and response. | ||||||
Pazopanib Hydrochloride | 635702-64-6 | sc-364564 sc-364564A | 10 mg 25 mg | $107.00 $230.00 | 1 | |
Pazopanib Hydrochloride exhibits a distinctive ability to disrupt PDGFR signaling by engaging in high-affinity interactions with the receptor's active site. This compound's unique structural conformation allows for the stabilization of an inactive receptor state, effectively preventing ligand-induced activation. Its interaction kinetics reveal a competitive inhibition pattern, characterized by a swift binding rate and prolonged dissociation time, which enhances its regulatory impact on cellular pathways. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib functions as a potent inhibitor of PDGFR, characterized by its selective binding to the receptor's ATP-binding pocket. This interaction alters the conformational dynamics of the receptor, promoting a shift towards an inactive state. The compound's unique molecular architecture facilitates strong van der Waals and hydrogen bonding interactions, resulting in a notable decrease in downstream signaling. Its kinetic profile showcases a rapid association phase, followed by a gradual dissociation, underscoring its effectiveness in modulating receptor activity. | ||||||
PD 161570 | 192705-80-9 | sc-361284 sc-361284A | 5 mg 25 mg | $112.00 $446.00 | 1 | |
PD 161570 acts as a selective antagonist of PDGFR, exhibiting a unique binding affinity that disrupts receptor dimerization. This compound engages in specific electrostatic interactions with key amino acid residues, leading to a conformational change that inhibits receptor activation. Its distinct molecular structure allows for enhanced stability in complex formation, while its reaction kinetics reveal a slow onset of inhibition, providing sustained modulation of PDGFR-mediated pathways. | ||||||
Dovitinib, Free Base | 405169-16-6 | sc-396771 sc-396771A | 10 mg 25 mg | $170.00 $350.00 | ||
Dovitinib, Free Base, functions as a selective inhibitor of PDGFR, characterized by its ability to interfere with receptor signaling through unique allosteric modulation. This compound exhibits specific hydrophobic interactions with the receptor's binding site, promoting a shift in the receptor's conformational landscape. Its kinetic profile indicates a gradual onset of action, allowing for prolonged engagement with PDGFR, which may influence downstream signaling cascades effectively. | ||||||
4,4′-Bis(4-aminophenoxy)biphenyl | 13080-85-8 | sc-267771 | 5 g | $100.00 | ||
4,4'-Bis(4-aminophenoxy)biphenyl acts as a modulator of PDGFR, showcasing distinctive binding dynamics that enhance receptor affinity. Its structural configuration facilitates strong π-π stacking interactions with aromatic residues, leading to altered receptor activation states. The compound's unique electronic properties contribute to its ability to stabilize specific conformations of PDGFR, potentially impacting the receptor's downstream signaling pathways and cellular responses. | ||||||